In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 351 to 392 of 392

TitleTypeExpected publication date
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Highly specialised technologyTBC
Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessmentHealth technology evaluation
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Total hip arthroplasty using the superpath approach for osteoarthritisInterventional procedures guidanceTBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Technology appraisal guidanceTBC
Transcatheter aortic valve implantation for native aortic valve regurgitationInterventional procedures guidance
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessmentHealth technology evaluation
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasiaInterventional procedures guidance
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891Technology appraisal guidanceTBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidanceTBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Type 2 diabetes in adults: management (medicines update)NICE guideline
Ublituximab for treating relapsing multiple sclerosis [ID6350]Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Urinary Tract Infection (recurrent): antimicrobial prescribingNICE guideline
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adultsInterventional procedures guidance
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Violence and Aggression: short-term management in mental health, health and community settingsNICE guidelineTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidance
VTS-270 for treating Niemann-Pick type C1 [ID1267]Highly specialised technologyTBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]Technology appraisal guidanceTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Women's and reproductive health guidelinesNICE guidelineTBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidance
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidanceTBC
Zio XT for detecting cardiac arrhythmiasMedical technologies guidanceTBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Technology appraisal guidanceTBC
Zuranolone for treating severe postnatal depression ID6431Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All